添加治疗与cenobamate已经在耐火焦的低剂量有效:一个前性观察性研究研究
Yulia Novitskaya1, Elisa Schütz1, Birgitta Metternich1
1Department of Neurosurgery, Freiburg Epilepsy Center, Medical Center, University of Freiburg, Freiburg, Germany.
塞诺巴马特有效地减少了治疗耐药焦点的成年人发作的频率. 这项实践研究表明,即使在低剂量中,也能很好地容忍诺巴的高效率和良好的耐受性.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 塞诺巴马特是一种具有双重作用机制的新型抗发作药物.
- 关键试验表明,赛诺巴马特在改善治疗耐药焦点的发作控制方面具有有效性.
研究的目的:
- 为了评估在焦点患者中切诺巴酸的实际有效性和耐受性.
- 在12个月的随访期内评估发作的结果和不良事件.
主要方法:
- 预期对112名耐火性焦点的成年患者进行随访,这些患者接受了塞诺巴补充疗法.
- 在治疗开始后的3,6个月和12个月评估结局和不良事件.
主要成果:
- 3个月后观察到每月发作频率显著降低,中位数为100毫克/天的塞诺巴剂量.
- 响应率 (≥50%的发作减少) 在12个月达到55%,其中19%实现了无发作.
- 副作用大多为轻度至中度,通过喜剧调整成功管理.
结论:
- 在现实环境中,雪诺巴在低剂量下显示出临床相关的疗效和良好的耐受性.
- 这种药物即使在与关键试验队列相比,药物耐药性较高的患者中也有效.
- 未来的数据支持赛诺巴作为耐火焦点的有价值的治疗选择.
更多相关视频
09:06Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
Published on: December 22, 2016
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Electroconvulsive Therapy
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
